Anavex Life Sciences Corp (AVXL)

[falconer66a]

“But, what’s an Avatar?”

AVATAR is PHASE 3. Quit shortchanging the facts. That is my point!

Well, yes, granted, the Rett study (Phase 3) is complete, with positive outcomes.

But how many equity investors know what an “AVATAR” is? Have they ever heard of “Rett syndrome?” Do they have any idea how big (well, how tiny) the Rett syndrome market is?

Anavex is not going to become a major pharmaceutical (with share prices to match) treating rare diseases like Rett. Stock market investors know the sizes of the Parkinson’s and Alzheimer’s markets. They are going to wait for Anavex to have Phase 3 data from those diseases that will prompt the FDA to approve blarcamesine. Until those readouts appear, there won’t be much of an AVXL share price gain.

Now, don’t get me wrong. As readers of my dozens of postings know, as a biologist I know, understand, can explain, and believe in the unique, novel Anavex MOA (mechanism of action). Nothing like it in all of pharmacology (acting propitiously on the sigma-1 receptor protein). When I get some more discretionary funds, I’ll be expanding my AVXL position. But the general market wants to see Phase 3 Parkinson’s and Alzheimer’s readouts. For them, that’s all that will count. Those are coming, soon enough.